ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest apnimed news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks apnimed across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Apnimed priced its IPO at $16 per share, raising $192 million and valuing the Cambridge, Mass. biotech above $600 million. The company's once-nightly sleep apnea pill awaits FDA approval, with a decision possible in the first quarter of 2027.
Summaries by ByteBrief